Experience of the Use of Trabectedin (ET-743, Yondelis™) in 21 Patients with Pre-treated Advanced Sarcoma from a Single Centre

Clinical Oncology

Volumn 19, Issue 8, 2007, Pages 572-576

  Roylance, R ^a,b   Seddon, B ^a   McTiernan, A ^a   Sykes, K ^a   Daniels, S ^a   Whelan, J ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Ecteinascidin 743; ET 743; sarcoma; trabectedin; Yondelis

Indexed keywords

ANTHRACYCLINE; ANTICOAGULANT AGENT; DEXAMETHASONE; IFOSFAMIDE; METOCLOPRAMIDE; TRABECTEDIN;

ADOLESCENT; ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER FUNCTION; LIVER TOXICITY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SARCOMA; SIDE EFFECT; SURVIVAL RATE; THERAPY DELAY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; SARCOMA; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548163662     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.05.006     Document Type: Article

References (18)

1. Pommier Y., Kohlhagen G., Bailly C., Waring M., Mazumder A., and Kohn K.W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35 41 (1996) 13303-13309
2. Zewail-Foote M., and Hurley L.H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42 14 (1999) 2493-2497
3. Bonfanti M., La Valle E., Fernandez Sousa Faro J.M., et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 14 3 (1999) 179-186
4. Takebayashi Y., Pourquier P., Zimonjic D.B., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7 8 (2001) 961-966
5. Taamma A., Misset J.L., Riofrio M., et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19 5 (2001) 1256-1265
6. Delaloge S., Yovine A., Taamma A., et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 19 5 (2001) 1248-1255
7. van Kesteren C., Twelves C., Bowman A., et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13 4 (2002) 381-393
8. Villalona-Calero M.A., Eckhardt S.G., Weiss G., et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 8 1 (2002) 75-85
9. Ryan D.P., Supko J.G., Eder J.P., et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 7 2 (2001) 231-242
10. Garcia-Carbonero R., Supko J.G., Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 8 (2004) 1480-1490
11. Yovine A., Riofrio M., Blay J.Y., et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22 5 (2004) 890-899
12. Le Cesne A., Blay J.Y., Judson I., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 3 (2005) 576-584
13. Garcia-Carbonero R., Supko J.G., Maki R.G., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23 24 (2005) 5484-5492
14. Laverdiere C., Kolb E.A., Supko J.G., et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98 4 (2003) 832-840
15. Van Glabbeke M., Verweij J., Judson I., and Nielsen O.S. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38 4 (2002) 543-549
16. Le Cesne A., Judson I., Crowther D., et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18 14 (2000) 2676-2684
17. Samuels B., Rushing D., Chawla S., et al. Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy. J Clin Oncol 22 (2004) 14S
18. Gomez J., Lazaro L., Guzman C., et al. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol 19 (2000) 187a